Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. [electronic resource]
Producer: 20180130Description: 72-80 p. digitalISSN:- 1528-4336
- Adult
- Aged
- Anti-Retroviral Agents -- administration & dosage
- CCR5 Receptor Antagonists -- administration & dosage
- Coinfection
- Cyclohexanes -- administration & dosage
- Double-Blind Method
- Female
- HIV Infections -- complications
- HIV-1 -- drug effects
- Hepacivirus -- drug effects
- Hepatitis B -- complications
- Hepatitis B virus -- drug effects
- Hepatitis C -- complications
- Humans
- Liver -- drug effects
- Male
- Maraviroc
- Middle Aged
- Placebos
- Triazoles -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.